Prosecution Insights
Last updated: August 06, 2026
Application No. 18/712,871

AN IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM-A OF CYANTRANILIPROLE

Non-Final OA §102§112
Filed
May 23, 2024
Priority
Nov 24, 2021 — IN 202141054091 +1 more
Examiner
JOHNSON, CHRISTOPHER LINDSAY
Art Unit
Tech Center
Assignee
Natco Pharma Limited
OA Round
1 (Non-Final)
52%
Grant Probability
Moderate
1-2
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
15 granted / 29 resolved
-8.3% vs TC avg
Strong +78% interview lift
Without
With
+77.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
35 currently pending
Career history
71
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
37.2%
-2.8% vs TC avg
§102
20.2%
-19.8% vs TC avg
§112
31.7%
-8.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 29 resolved cases

Office Action

§102 §112
DETAILED ACTION This office action is in response to the Applicant’s filing dated May 23rd, 2024. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a 371 of PCT/IN2022/051018 filed on November 22nd, 2022; and claims benefit of foreign priority of IN202141054091 filed on November 24th, 2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Status of Claims Claims 1-4 are pending in the instant application. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 4, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Oberholzer et al (WO 2010/056720 A1), cited in the Applicant’s IDS filed on July 17th, 2024. Regarding claims 1-4, Oberholzer teaches a method of preparing polymorph A of cyantraniliprole shown below (page 2, lines 18-25; page 14, claim 1): PNG media_image1.png 342 429 media_image1.png Greyscale comprising heating polymorph B of cyantraniliprole in a solvent; wherein suitable solvents can be methylcyclohexane or xylene (page 7, lines 1-3, 11 and 13). Oberholzer further teaches that conversion proceeds to near 100% completion and high yields at temperatures not exceeding 100°C (page 7, lines 22-24; page 15, claims 7-9). Oberholzer discloses that polymorph b of cyantraniliprole typically comprises water while polymorph A of cyantraniliprole is anhydrous; leading to water being a byproduct of the conversion; teaching that azeotropic distillation can be used to remove water from the polymorph A cyantraniliprole product (page 7, lines 13-16); and that after conversion the mixture is cooled to 25°C and the product isolated (page 8, lines 11-12; page 10, line 6). Oberholzer further discloses that because polymorph A of cyantraniliprole has low water solubility, it can easily be isolated by filtration and water evaporation (page 7, lines 25-27). Thus, the teachings of Oberholzer anticipate the process of preparing of instant claims 1-4. Conclusion Claims 1-4 are rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L JOHNSON whose telephone number is (571)272-1672. The examiner can normally be reached Monday - Friday 08:00AM - 5:00PM EST with Flex on Fridays. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.L.J./Examiner, Art Unit 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

May 23, 2024
Application Filed
Jul 17, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12691111
SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES
3y 11m to grant Granted Jul 28, 2026
Patent 12686682
NEW INDAZOLE ACETYLENE DERIVATIVES
3y 1m to grant Granted Jul 21, 2026
Patent 12649745
AMINO-PYRIMIDINE CYCLO-AMIDES
3y 6m to grant Granted Jun 09, 2026
Patent 12643862
NEW RYLENE DICARBOXIMIDES
3y 10m to grant Granted Jun 02, 2026
Patent 12637426
1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
4y 1m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
52%
Grant Probability
99%
With Interview (+77.8%)
3y 4m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 29 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month